XBiotech Inc.
About XBiotech Inc.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$45.5M
- Total assets
- $150.1M
- Market cap
- $72.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$55.7M
- Income tax
- $235.0K
- Net income
- -$45.5M
- EPS (basic)
- $-1.49
- EPS (diluted)
- $-1.49
Balance sheet
- Total assets
- $150.1M
- Current assets
- $127.0M
- Total liabilities
- $9.7M
- Current liabilities
- $7.9M
- Shareholders’ equity
- $140.3M
Cash flow
- Operating cash flow
- -$39.9M
- Investing cash flow
- -$289.0K
- Financing cash flow
- -$10.2M
- Net cash flow
- -$47.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $72.3M
- EPS (diluted)
- $-1.49
- Shares outstanding
- 30.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 15, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $45.5M.
- Trading 32% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review XBiotech Inc..
Write a review
News about XBiotech Inc.
News & sentiment via Polygon.io
